expanding the realm of possible... About R&D Investors Careers about addex executive management board of directors Addex was founded in 2002 by pharmaceutical industry drug developers from Roche and GlaxoSmithKline and top European venture capital investors. Addex scientists developed a scalable process for discovering and developing orally available drug-like allosteric modulators. Recognizing that their innovations could become an industrial allosteric drug discovery platform, management began building the world leading allosteric modulator discovery and development process. Although a handful of allosteric modulators were discovered by serendipity and are now marketed drugs, allosteric molecules are elusive and conventional high throughput screening systems are not sensitive enough to identify them using standard molecular libraries and screening tools; furthermore, most chemical libraries are not adequately populated with molecules that have allosteric characteristics. Over the last decade, Addex has attracted some of the world's leading experts in allosteric modulation and built an allostery-focused chemical library and high throughput screening assays specifically tailored for detecting allosteric modulators. In order to leverage and build upon its first mover advantage, the company integrated drug development capabilities including in vitro, preclinical and clinical development experts with significant pharmaceutical industry experience. Advised by some of the world's leading scientists, the team has focused not only on building knowledge of allosteric modulation but, more importantly, developing orally available allosteric drugs for important unmet medical need. Validating its platform and internally discovered novel chemical entities, Addex has a diverse pipeline of proprietary compounds that address diseases of the central nervous system, metabolism and inflammation. In addition, a discovery partnership with Janssen Pharmaceuticals Inc. has advanced a lead molecule into Phase II testing for schizophrenia. Because allosteric drugs offer different target product profile than conventional drugs - even at the same target - they are well differentiated and offer multiple competitive advantages. For example, allosteric drugs can be more specific and selective for their target, making them safer and more effective than conventional drugs at the same target. Injectable protein therapeutic drugs can be replaced by oral allosteric modulators with differentiated safety and efficacy, a better cost of goods and more patient friendly administration. Addex has a dominant, growing intellectual property portfolio covering the composition of matter, methods of use and discovery technologies for allosteric modulators. > back Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction ADX71441 reversed somatic signs of withdrawal in nicotine-dependent mice and reversed hyperalgesia, further supporting the use of GABA-B activation as a strategy to achieve smoking cessation Geneva, Switzerland, 10... Addex Shareholders Approve All Board Proposals at Annual General Meeting Geneva, Switzerland, 30 June 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all... Addex Therapeutics Publishes Annual General Meeting Agenda Geneva, Switzerland, 12 June 2014 - Addex Therapeutics (SIX:... Addex Therapeutics Publishes Annual Report 2013 Geneva, Switzerland, 30 May 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press release of 30 April... Addex Therapeutics Reports 2013 Financial Results 2013 Financial Highlights Significant reduction in 2013 cash utilization of CHF12.3 million, significantly below guidance of CHF15 million, CHF1.6 million used in second half of 2013... home contact sitemap